Literature DB >> 8096975

Development of oral iron chelator L1.

C Hershko.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8096975     DOI: 10.1016/0140-6736(93)92444-x

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

Review 1.  World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients.

Authors:  Christina N Kontoghiorghe; Nicholas Andreou; Katerina Constantinou; George J Kontoghiorghes
Journal:  World J Methodol       Date:  2014-09-26

2.  Deferiprone (L1) induced conformation change of hemoglobin: A fluorescence and CD spectroscopic study.

Authors:  D Chakraborty; M Bhattacharyya
Journal:  Mol Cell Biochem       Date:  2000-01       Impact factor: 3.396

Review 3.  Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases.

Authors:  G J Kontoghiorghes
Journal:  Indian J Pediatr       Date:  1993 Jul-Aug       Impact factor: 1.967

Review 4.  Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.

Authors:  George J Kontoghiorghes; Katia Neocleous; Annita Kolnagou
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

5.  Iron chelators as therapeutic agents against Pneumocystis carinii.

Authors:  G A Weinberg
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

Review 6.  The History of Deferiprone (L1) and the Paradigm of the Complete Treatment of Iron Overload in Thalassaemia.

Authors:  George J Kontoghiorghes; Marios Kleanthous; Christina N Kontoghiorghe
Journal:  Mediterr J Hematol Infect Dis       Date:  2020-01-01       Impact factor: 2.576

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.